Virtual biology company Turbine has raised $25 million in a Series B funding round. The new investment will help the company grow its virtual cell technology and expand into immunology. This marks a big step for Turbine as it moves beyond its initial focus on oncology research.

Funding Highlights and Investor Support

The funding round was led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and existing investors including Accel, MSD Global Health Innovation, and Mercia. While the exact financial details of the deal weren’t disclosed, the $25 million boost is a significant milestone for the company.

This investment also underscores a growing confidence in AI-powered drug discovery platforms emerging from Central and Eastern Europe. Experts see this region as a hotbed for biotech innovation, and Turbine is seen as a standout in virtual biology technology.

Strategic Collaborations and Future Plans

Alongside the funding, Turbine announced a new collaboration with a top 10 pharmaceutical company focused on immunology. This partnership marks Turbine’s first major move outside of cancer research. The company will train its virtual assays on proprietary immune system datasets provided by the partner.

The goal is to model immune cell behaviors, test complex drug combinations, and identify which patient groups might benefit most. This approach aims to speed up drug development and improve the precision of treatments, especially for immune-related diseases.

With the new funds, Turbine plans to expand its platform to cover more types of assays across drug discovery and translational medicine. Its lab-in-the-loop system allows researchers to run large-scale in silico experiments, helping them narrow down promising hypotheses before moving to real-world labs. This no-code interface is designed to seamlessly integrate into existing pharma workflows, making virtual experiments more accessible.

The company’s focus on virtual assays and datasets will also help generate proprietary data. These datasets will refine Turbine’s virtual cell models across different tissue types and assay formats, leading to more accurate simulations and predictions.

The partnership with the pharmaceutical company will involve training virtual models on immune datasets, enabling insights into immune cell behavior and drug interactions. This could revolutionize how new immunotherapies are developed and personalized for patients.

Overall, Turbine’s move into immunology and its recent funding showcase the growing role of AI in drug discovery. By virtualizing complex biological processes, the company aims to speed up research, reduce costs, and bring innovative treatments to market faster.

Inspired by

• https://justainews.com/companies/funding-news/turbine-raises-25m-series-b-for-virtual-biology/